Home
overview
The global anti-infective market is currently valued at US$66.5 billion with antibacterial agents accounting for over 50% of sales. The antibacterial market is set to grow to over US$45.0 billion by 2012, driven by the uptake of newer antibacterial agents such as glycopeptides and carbapenems which demonstrate resistance to methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) as well as other emerging strains.

Pharmaceutical companies continue to develop a new generation of antibacterial agents such as cephalosporins, macrolides and quinolones to overcome the major issue of drug resistance but this is not without the struggle and threat of bacterial resistance.

By attending SMi’s 10th Annual Superbugs & Superdrugs; A focus on antibacterials conference, you will be able to:

DISCOVER the main antibacterial targets that are worth investing in.
LEARN state-of-the-art therapeutic mAbs for bacterial infections.
UNDERSTAND pioneering antisense strategies for bacteria.
DIVE into the R&D pipeline and inspect the novel advances in drug development.
FAMILIARISE yourself with up-to-date regulatory aspects.
UPDATES on Phage therapy, quorum sensing, and diagnostics.
ASCERTAIN pioneering developments in both gram-positive and gram-negative bacteria.
Do not miss this opportunity to find out the incentives for development and learn of the advances in the pipeline for antibacterials.
Hear international case studies and expert opinions from leaders in the field, including:
  • Dr Kenneth Tack, Executive Director, Targanta
  • Dr Neil S Ryder, Executive Director, Infectious Diseases, Novartis
  • Dr Paul Miller, Executive Director, Anti-Bacterials, Pfizer
  • Dr Brian Noonan, Director of Molecular Bioscience, AstraZeneca
  • Dr Jeff Hermes, Senior Director Microbil Biochemistry, Merck
  • Dr Monique Twynholm, Director, Anti-Infectives, GlaxoSmithKline
  • Dr E David G McIntosh, Medical Director Infectious Diseases, Wyeth
  • Dr Lloyd Czaplewski, Director of Research, Prolysis
  • Prof. Malcolm G. P. Page, Head of Biology, Basilea
  • Dr William Weiss, Director, Drug Evaluation, Cumbre Pharmaceuticals
  • Dr Beatrice Allain, Director, Therapeutic Division, Biophage Pharma
  • Dr Ly Tam Phan, Senior Director Medicinal Chemistry, Enanta Pharmaceuticals
  • Dr Jeff Alder, Vice Presedent, Drug Discovery and Evaluation, Cubist Pharmaceuticals
  • Dr Nafsika Georgopapadakou, Vice President of Research, Novabay Pharmaceuticals

  • Dr Albert Collinson, Chief Business Officer, Rib - X - Pharmaceuticals

  • Dr Nora Kaarela, Chief Executive Officer, IPSAT Therapies

  • Dr Hans-Henrik Kristensen, Senior manager, Novozymes A / S

  • Dr Thomas Henkel, CEO, Intermed Discovery GmBh

Who should attend Superbugs & Superdrugs?
You should attend this conference if you are an Executive, Director, Chemist or Scientist working in the pharmaceutical or biotech industries within:
  • Microbiology
  • Immunology
  • Infectious Diseases
  • Medicinal Chemistry
  • Clinical Pharmacology
  • Drug Discovery
  • New Product Development
  • Scientific Affairs
  • Licensing
  • Antibiotics
  • Infection Discovery
  • Drug evaluation
  • Molecular Biotechnology
  • Drug Development
  • Project Management
  • Preclinical Development
  • Portfolio Management

This year's conference is being attended by the following companies:

  • Novartis
  • Novozymes A / S
  • AM-Pharma BV
  • AstraZeneca
  • GlaxoSmithKline
  • LEO Pharma
  • Wyeth
  • Summit plc
  • Plant Bioscience (PBL)
  • Mutabilis SA
  • Intermed Discovery GmBh
  • Anacor Pharmaceuticals Inc
  • Janssen-Cilag Limited
  • Meiji Seika Kaisha
  • NOVEXEL
  • Rib-X Pharmaceuticals
  • Prolysis
  • Novabay Pharmaceuticals
  • IPSAT Therapies
  • Merck
  • Pfizer
  • Aquapharm Biodiscovery
  • Arpida
  • Enanta
  • Cubist Pharmaceuticals
  • Eurofins Medinet
  • University Medical Centre Utrecht
  • Targanta Therapeutics
  • Cipan - Companhia Industiral Produtora De Antibioticos S A
  • Combinature Biopharma A G
  • Aquapharm Biodiscovery
  • Cumbre Pharmaceuticals
  • Basilea
  • Biophage Pharma

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Malcolm Page

Malcolm Page, Head, Biology, Basilea Pharmaceutica

9:10 CASE STUDY OF DRUG DEVELOPMENT – ORITAVANCIN

Kenneth Tack

Kenneth Tack, Senior Director, Targanta Therapeutics

  • History of the compound
  • Chemistry
  • In-vitro activity
  • Animal Studies
  • Clinical Trials
  • 9:50 OVERCOMING RESISTANCE BY DESIGN

    Albert Collinson

    Albert Collinson, Chief Business Officer, Rib - X - Pharmaceuticals Inc

  • Attacking multi-drug resistant bacteria via the ribosome
  • Discovery and development of new highly potent antibiotics
  • Achieving success in the clinic against resistant bacteria
  • 10:30 Morning Coffee

    10:50 PHAGE THERANOSTIC

    Beatrice Allain

    Beatrice Allain, Director, Biophage Pharma Inc

  • Presentation of phage therapy
  • Recent advances in phage therapy
  • Diagnostic as pre-requisite to efficient phage therapy
  • Advance in rapid diagnostic
  • Phage-Theranostic
  • 11:30 ALTERNATIVE SOLUTIONS TO PREVENTING HOSPITAL INFECTIONS AND ANTIBIOTIC RESISTANCE

    Nora Kaarela

    Nora Kaarela, Chief Executive Officer, IPSAT Therapies

  • The protective role of the intestinal microflora
  • Secondary infections and antibiotic resistance - unwanted "companions" of antibiotic treatment
  • Novel approach to preserve intestinal microflora during antibiotic treatment
  • Latest results from Phase IIB studies
  • 12:10 BACTERIAL DRUG RESISTANCE

    Jeffrey Alder

    Jeffrey Alder, Global Clinical Microbiology, Bayer Healthcare

  • Different and conflicting criteria for drug resistance
  • Reporting bias in drug resistance: over or under reported?
  • Drug Resistance and Clinical failure: cause and effect?
  • Impact of Drug Resistance criteria on Drug Discovery and Development
  • 12:50 Networking Lunch

    13:50 NEW APPROACHES TO OLD TARGETS

    David  McIntosh

    David McIntosh, Medical Director, Infectious Diseases, Wyeth

  • Tetracyclines act by inhibiting bacterial protein synthesis
  • The efficacy of tetracyclines has been compromised by the development of resistance
  • Efflux is a powerful form of resistance compromising the tetracyclines
  • Tigecycline is a glycylcycline, developed to overcome mechanisms of tetracycline resistance
  • 14:30 THE SEARCH FOR NOVEL ANTIBACTERIAL AGENTS

    Brian Noonan

    Brian Noonan, Director of Molecular Bioscience, Infection Discovery, AstraZeneca

  • The challenge of antibacterial lead generation
  • Approaches to identifying novel hit compounds
  • Turning hits into leads
  • 15:10 Afternoon Tea

    15:30 A BROAD SPECTRUM BETA LACTAMASE INHIBITOR TO ADDRESS GRAM NEGATIVE RESISTANCE

    Christine Miossec

    Christine Miossec, Biology, NOVEXEL

  • Increasing prevalence in ESBLs, class A carbapenemases, and Gram negative pathogens producing multiple ß-lactamases
  • No new classes of antibiotics in development to address Gram negative resistance
  • ß-lactam plus ß-lactamase inhibitor proven strategy; available agents class A only
  • NXL104 has a promising profile
  • Addressing clinical and regulatory challenges in development of ß-lactam, ß-lactamase inhibitor combinations
  • 16:10 MULTIDRUG-RESISTANT GRAM-NEGATIVE BACTERIA

    Malcolm Page

    Malcolm Page, Head, Biology, Basilea Pharmaceutica

  • Problem pathogens (drug-resistance in E. coli, K. Pneumoniae, P. aeruginosa and A. baumannii)
  • Resistance mechanisms in E. coli and K. pneumoniae
  • Resistance mechanisms in P. aeruginosa and A. baumannii
  • Activity of new agents, and compounds in late-stage clincal development, against MDR
  • Activity of experimental compounds in early stage clinical development
  • 16:50 TWO NEW ANTIBACTERIALS WITH NOVEL MECHANISMS OF ACTION

    Lloyd Czaplewski

    Lloyd Czaplewski, Director, Research, Prolysis

  • Use of fragment-based drug design & whole cell screening to create new antibacterials
  • Characterisation of FtsZ inhibitors as targeted anti-staphylococcal & anti-clostridial agents
  • Potent GyrB inhibitors active against resistant Gram-positives and community-acquired RTI’s
  • 17:30 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Neil Ryder

    Neil Ryder, Executive Director, Novartis Institutes for Biomedical Research Inc.

    9:10 ANTIBACTERIAL DRUG RESISTANCE

    Neil Ryder

    Neil Ryder, Executive Director, Novartis Institutes for Biomedical Research Inc.

  • Basic mechanisms of resistance
  • Common features of bacteria
  • Impact of resistance in selection of drug targets, with some recent examples
  • Advances in antibacterial drug discovery
  • How this can be compared to antifungal drug discovery
  • The road ahead
  • 9:50 CLINICAL DEVELOPMENT OF ANTIBIOTICS IN THE 21ST CENTURY

    Monique Twynholm

    Monique Twynholm, Associate Director, Anti-infectives, GlaxoSmithKline

  • Unmet medical need
  • Current hurdles in Antibiotic clinical development
  • Innovative study designs
  • Placebo controlled or superiority studies
  • Patient reported outcome measures in clinical trials
  • 10:30 Morning Coffee

    10:50 CHEMICAL POST-EVOLUTION OF ANTIBACTERIAL NATURAL PRODUCTS

    Paul Miller

    Paul Miller, Executive Director of Antibacterials , Pfizer

  • Examining lead structure variants
  • Structural and Physiochemical requirements for antibacterial activity
  • What is the track record for the success of natural products?
  • 11:30 PLECTASIN DERIVATIVE NZ2114

    Hans-Henrik Kristensen

    Hans-Henrik Kristensen, Senior manager, Novozymes A / S

  • Potent in vitro activity against gram-positive bacteria including MRSA and VRSA
  • Therapeutic activity in animal models of infection
  • Novel mechanism of action compared to clinically used antibiotics
  • Pre-clinical tox-safety data
  • 12:10 NATURAL PRODUCT (NP) BASED ANTIBACTERIALS

    Thomas Henkel

    Thomas Henkel, Chief Executive Officer, Intermed Discovery GmBh

  • Some successes from the past and actual examples
  • What are the obstacles?
  • General potential of Natural Products - a prediction
  • Perspectives for the future
  • 12:50 Networking Lunch

    13:50 STRATEGIES TO BROADEN CARBAPENEM ACTIVITY VS. RESISTANT PATHOGENS

    Jeff Hermes

    Jeff Hermes, Senior Director, Merck

  • Carbapenem antibiotics have been a mainstay of empiric therapy for two decades
  • However, carbapenem resistance in key Gram-negative pathogens has become problematic in nosocomial infections (e.g. P. aeruginosa and K. pneumoniae)
  • Few therapeutic options exist to cover these multi-drug resistant Gram-negative pathogens
  • In addition, MRSA prevalence is significant and marketed carbapenems never afforded coverage of this increasingly important Gram-positive organism
  • Can adjunct agents rescue the widely utilized carbapenem class of antibiotics?
  • 14:30 GASTROINTESTINAL DISEASES

    William Weiss

    William Weiss, Director, Drug Evaluation, Cumbre Pharmaceuticals

  • Background of disease states
  • Prevalence / epidemiology / resistance
  • Target product profiles
  • Therapy: standard of care
  • New and emerging agents
  • 15:10 Afternoon Tea

    15:30 TACKLING B-LACTAMASE-ASSOCIATED RESISTANCE MECHANISMS

    Nafsika Georgopapadakou

    Nafsika Georgopapadakou, Vice President Research, NovaBay Pharmaceuticals

  • The ABCs of B-lactamases
  • Approaches to reduce resistance:  attacking v. co-opting B-lactamases
  • What properties should an inhibitor have?  A pro-drug?
  • Emerging micro-organisms and the hurdles they pose
  • Multidrug resistance - its impact on B-lactamase-associated resistance
  • Future trends and therapeutic options
  • 16:10 NEW BICYCLOLIDES ACTIVE AGAINST MRSA AND VRE

    Ly Phan

    Ly Phan, Director, Medicinal Chemistry, Enanta Pharmaceuticals

  • Recent advances in macrolide research against  MRSA and VRE
  • 16:50 Chairman’s Closing Remarks and Close of Conference

    +

    Workshops

    PHAGE THERANOSTIC: A safe and integrated approach for the management of superbugs
    Workshop

    PHAGE THERANOSTIC: A safe and integrated approach for the management of superbugs

    Crowne Plaza Hotel - The City
    8th April 2008
    London, United Kingdom

    Crowne Plaza Hotel - The City

    19 New Bridge Street
    London EC4V 6DB
    United Kingdom

    Crowne Plaza Hotel - The City

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.